Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
NEONAX
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
- NCT02047513 ↗
- Completed
- AIO-Studien-gGmbH
- Focused
We haven't built an HCP commentary report on NEONAX (nab-paclitaxel plus gemcitabine in resectable pancreatic ductal adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NEONAX so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 7 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Plus Adjuvant or Only Adjuvant Nab-Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer: A Prospective, Randomized, Controlled, Phase II Study of the AIO (Working Group for Medical Oncology From the German Cancer Society) Pancreatic Cancer Group
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Resectable Pancreatic Cancer; Ductal Adenocarcinoma of the Pancreas
- Interventions
- perioperative nab-paclitaxel/gemcitabine; adjuvant nab-paclitaxel/gemcitabine
- Arms
- perioperative nab-paclitaxel/gemcitabine · Experimental
- adjuvant nab-paclitaxel/gemcitabine · Experimental
- Enrollment
- 127
- Primary outcomes
- Time to Disease free survival (DFS)
- Sponsor
- AIO-Studien-gGmbH with Celgene, ClinAssess GmbH
- Start
- Jul 2015
- Primary completion
- Apr 2021
- Results posted
- No
- Registry record
- NCT02047513 · updated Jun 15, 2023
Publications
linked from the registry- Seufferlein T, Uhl W, Kornmann M, Algul H, Friess H, Konig A, Ghadimi M, Gallmeier E, Bartsch DK, Lutz MP, Metzger R, Wille K, Gerdes B, Schimanski CC, Graupe F, Kunzmann V, Klein I, Geissler M, Staib L, Waldschmidt D, Bruns C, Wittel U, Fichtner-Feigl S, Daum S, Hinke A, Blome L, Tannapfel A, Kleger A, Berger AW, Kestler AMR, Schuhbaur JS, Perkhofer L, Tempero M, Reinacher-Schick AC, Ettrich TJ. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023 Jan;34(1):91-100. doi: 10.1016/j.annonc.2022.09.161. Epub 2022 Oct 7. PubMed 36209981
- Ettrich TJ, Berger AW, Perkhofer L, Daum S, Konig A, Dickhut A, Wittel U, Wille K, Geissler M, Algul H, Gallmeier E, Atzpodien J, Kornmann M, Muche R, Prasnikar N, Tannapfel A, Reinacher-Schick A, Uhl W, Seufferlein T. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer. 2018 Dec 29;18(1):1298. doi: 10.1186/s12885-018-5183-y. PubMed 30594153